Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of MK-0616 (Enlicitide) in Hypercholesterolemia
NCT05261126Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 8
01
Overview
A Phase 2 trial of enlicitide in hypercholesterolemia, sponsored by Merck & Co.. Started Mar 2022; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05261126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05261126.